BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

942 related articles for article (PubMed ID: 21504223)

  • 1. A comprehensive support vector machine binary hERG classification model based on extensive but biased end point hERG data sets.
    Shen MY; Su BH; Esposito EX; Hopfinger AJ; Tseng YJ
    Chem Res Toxicol; 2011 Jun; 24(6):934-49. PubMed ID: 21504223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico binary classification QSAR models based on 4D-fingerprints and MOE descriptors for prediction of hERG blockage.
    Su BH; Shen MY; Esposito EX; Hopfinger AJ; Tseng YJ
    J Chem Inf Model; 2010 Jul; 50(7):1304-18. PubMed ID: 20565102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. hERG classification model based on a combination of support vector machine method and GRIND descriptors.
    Li Q; Jørgensen FS; Oprea T; Brunak S; Taboureau O
    Mol Pharm; 2008; 5(1):117-27. PubMed ID: 18197627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the hERG1 pore domain.
    Durdagi S; Duff HJ; Noskov SY
    J Chem Inf Model; 2011 Feb; 51(2):463-74. PubMed ID: 21241063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A binary QSAR model for classification of hERG potassium channel blockers.
    Thai KM; Ecker GF
    Bioorg Med Chem; 2008 Apr; 16(7):4107-19. PubMed ID: 18243713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective validation of a comprehensive in silico hERG model and its applications to commercial compound and drug databases.
    Doddareddy MR; Klaasse EC; Shagufta ; Ijzerman AP; Bender A
    ChemMedChem; 2010 May; 5(5):716-29. PubMed ID: 20349498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining cluster analysis, feature selection and multiple support vector machine models for the identification of human ether-a-go-go related gene channel blocking compounds.
    Nisius B; Göller AH; Bajorath J
    Chem Biol Drug Des; 2009 Jan; 73(1):17-25. PubMed ID: 19152631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Classification models for HERG inhibitors by counter-propagation neural networks.
    Thai KM; Ecker GF
    Chem Biol Drug Des; 2008 Oct; 72(4):279-89. PubMed ID: 18844674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel approach using pharmacophore ensemble/support vector machine (PhE/SVM) for prediction of hERG liability.
    Leong MK
    Chem Res Toxicol; 2007 Feb; 20(2):217-26. PubMed ID: 17261034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive toxicology modeling: protocols for exploring hERG classification and Tetrahymena pyriformis end point predictions.
    Su BH; Tu YS; Esposito EX; Tseng YJ
    J Chem Inf Model; 2012 Jun; 52(6):1660-73. PubMed ID: 22642982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A composite model for HERG blockade.
    Kramer C; Beck B; Kriegl JM; Clark T
    ChemMedChem; 2008 Feb; 3(2):254-65. PubMed ID: 18061919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Catch-22 of Predicting hERG Blockade Using Publicly Accessible Bioactivity Data.
    Siramshetty VB; Chen Q; Devarakonda P; Preissner R
    J Chem Inf Model; 2018 Jun; 58(6):1224-1233. PubMed ID: 29772901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insights for human ether-a-go-go-related gene potassium channel inhibition using recursive partitioning and Kohonen and Sammon mapping techniques.
    Ekins S; Balakin KV; Savchuk N; Ivanenkov Y
    J Med Chem; 2006 Aug; 49(17):5059-71. PubMed ID: 16913696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bias-correction of regression models: a case study on hERG inhibition.
    Hansen K; Rathke F; Schroeter T; Rast G; Fox T; Kriegl JM; Mika S
    J Chem Inf Model; 2009 Jun; 49(6):1486-96. PubMed ID: 19435326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Similarity-based SIBAR descriptors for classification of chemically diverse hERG blockers.
    Thai KM; Ecker GF
    Mol Divers; 2009 Aug; 13(3):321-36. PubMed ID: 19219559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
    Wiśniowska B; Mendyk A; Fijorek K; Glinka A; Polak S
    J Appl Toxicol; 2012 Oct; 32(10):858-66. PubMed ID: 22761000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In silico prediction of hERG inhibition.
    Jing Y; Easter A; Peters D; Kim N; Enyedy IJ
    Future Med Chem; 2015; 7(5):571-86. PubMed ID: 25921399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of hERG potassium channel affinity by the CODESSA approach.
    Coi A; Massarelli I; Murgia L; Saraceno M; Calderone V; Bianucci AM
    Bioorg Med Chem; 2006 May; 14(9):3153-9. PubMed ID: 16426850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indexing molecules for their hERG liability.
    Rayan A; Falah M; Raiyn J; Da'adoosh B; Kadan S; Zaid H; Goldblum A
    Eur J Med Chem; 2013 Jul; 65():304-14. PubMed ID: 23727540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel structure-based virtual screening model for the hERG channel blockers.
    Du L; Li M; You Q; Xia L
    Biochem Biophys Res Commun; 2007 Apr; 355(4):889-94. PubMed ID: 17331468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.